Your fact-checks will appear here
Part of Earth that lies north of the equator
Early evidence shows 2025–26 flu vaccines likely cut medically attended illness and hospitalizations roughly in half in settings where the same viruses circulated as in the Southern Hemisphere (about ...
Early real-world data indicate are substantially protective against severe outcomes: estimates from the and international analyses place vaccine effectiveness (VE) against influenza-associated hospita...
The 2025–2026 Northern Hemisphere flu vaccines are trivalent and chosen to target one H1N1 A strain, one H3N2 A strain, and one B/Victoria-lineage strain; U.S. regulators (FDA/CDC) recommended these c...
Early real-world data from the UK indicate the 2025–26 vaccine is reducing hospital attendance for pediatric H3N2 cases by about 70–75% and by roughly 30–40% in adults, even as a drifted H3N2 “subclad...
Public reporting from CDC and partner networks indicates there is no single fixed calendar date for a U.S. influenza vaccine effectiveness (VE) estimate for the 2025–26 season; instead CDC and its sur...
Real-world effectiveness studies for the 2024–25 and early 2025 seasons generally showed moderate protection against medically attended illness and hospitalization — typically roughly 37%–63% in U.S. ...
Randomized trial data for 2025–2026 influenza vaccines are limited in the available reporting; most contemporary efficacy/effectiveness figures come from observational VE networks and Southern Hemisph...
Solar geoengineering—mostly studied as stratospheric aerosol injection (SAI) or marine cloud brightening—could cool the planet but carries a range of environmental side effects that researchers and ag...
Seasonal updates to H3N2 components of influenza vaccines are driven by coordinated global surveillance, laboratory antigenic and genetic analyses, and formal recommendations by international and nati...
The Centers for Disease Control and Prevention (CDC) does not publish a fixed calendar date for U.S.-specific influenza vaccine effectiveness (VE) estimates for a given season; instead, CDC’s four U.S...
If Australia scores marginally higher than New Zealand on published survivability indices, that difference does not by itself make relocating "necessary"; the Risk Analysis study ranked Australia top ...
CDC’s public pages do not publish age‑specific 2025–2026 H3N2 vaccine‑effectiveness (VE) point estimates by age group; early real‑world VE figures come from UK Health Security Agency and related repor...
The 2025 influenza vaccine delivered , with stronger protection reported against influenza B and H1N1 subtypes and weaker protection against H3N2. These findings are preliminary and derived from surve...